Abstract:Heterobimetallic complexes containing ferrocene and late transition metal complexes with nitrogen ligands form different geometrical isomers, with distinct electrochemical features and antiproliferative activity. Bis(2‐picolyl)amine (bpa), iminodiacetamide (imda), and bis‐1,2,3‐triazole (bta) ferrocene ligands (L) with and without an aliphatic linker were prepared by multi‐step synthesis. The cis‐fac, trans‐fac, or mer stereochemistry of their ML2 complexes with Ni(II), Cu(II), Cd(II), and Zn(II) was studied in the solid state (infrared [IR] and single‐crystal X‐ray diffraction [SC‐XRD]), in solution (nuclear magnetic resonance [NMR] and cyclic voltammetry [CV]) and by density functional theory (DFT) calculations. Crystal structures were determined for bpa ligand 7, and complexes [Ni(1)2](NO3)2 (1Ni), [Cu(8)2]OTf2 (8Cu), [Ni(10b)2](NO3)2 (10bNi), and [Cu(10b)2]OTf2 (10bCu). The bond strength of the central metal ion to the ligand amine nitrogen atom was studied by NMR, electrochemistry, and DFT. The information on redox‐active centers, electron transfer properties of ferrocene ligands (L), and their in situ complexation with zinc(II) and nickel(II) ions were obtained by voltammetric analysis. In addition, DFT calculations showed that the electron ionization in ML2 complexes occurs from one of the ferrocene units, leaving the electronic structure of the other ligand intact, while some of the expelled electron density is recovered by the adjacent amine through resonance. This effect is more pronounced in the free ligands, because the eventual amine resonance in ML2 needs to balance its Zn(II) coordination participation, which justifies why they show higher ionization energies over free ligands. Moreover, due to lower steric hindrance, the N(amino)–Zn(II) coordination is additionally stronger in 1:1 ML complexes, which makes their electron depletion further more demanding. If compared with the clinical drug cisplatin, complexes of bpa 1Ni and imda 2Ni showed a better effect on the viability of different tumor cell lines and better selectivity towards normal cells. Treatment with 1Ni and 2Ni causes an increase of cells in the S phase of the cell cycle and leads to the accumulation of cells in G0/G1. A decrease in the expression level of anti‐apoptotic marker Bcl‐2 upon treatment with both compounds together with increased amount of Annexin V‐FITC positive cells implied apoptosis as the mode of cell death.

A novel ferrocene-palladium metal complex: synthesis, single crystal structure, in vitro cytotoxicity study and molecular docking

Novel ferrocene cyclopalladated compounds: Synthesis, and in‐vitro antitumor activity study

New ferrocene cyclopalladated compounds: synthesis, X-ray single crystal structure and in vitro anticancer activity study

Dithiocarbazate–Fe III , −Co III , −Ni II , and −Zn II Complexes: Design, Synthesis, Structure, and Anticancer Evaluation

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Manipulating Fe(II) spin states to achieve higher anti-tumor cell activities in multinuclear complexes

Configurationally regulated half-sandwich iridium(III)-ferrocene heteronuclear metal complexes: Potential anticancer agents

Late transition metal complexes of ferrocene‐containing nitrogen ligands: Coordination chemistry, electron transfer properties, and tumor cell viability

New Potential Anticancer Agent Of Carborane Derivatives: Selective Cellular Interaction And Activity Of Ferrocene-Substituted Dithio-O-Carborane Conjugates

Crystal structure, in vitro cytotoxicity, DNA binding and DFT calculations of new copper (II) complexes with coumarin-amide ligand

Synthesis and Anticancer Properties of Heterobimetallic Fe(II)/Pd(II) Complexes Bearing Different Butadienyl Fragments

Decoration of Cisplatin on 2D Metal-Organic Frameworks for Enhanced Anticancer Effects through Highly Increased Reactive Oxygen Species Generation.

Monofunctional Supramolecular Pt(II) Complexes: Synthesis, Single Crystal Structure, Anticancer Activity, E. Coli Growth Retardation and DNA Interaction Study

Anticancer behaviour of 2,2′-(pyridin-2-ylmethylene)bis(5,5-dimethylcyclohexane-1,3-dione)-based palladium(II) complex and its DNA, BSA binding propensity and DFT study

Syntheses, Electrochemistry and Crystal Structure Studies of Novel Cis-Configuration Biferrocene Trinuclear Complexes

Antiproliferative activity of Fe(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes of dithiocarbamate: synthesis, structural characterization, and thermal studies

Addition of Ethynylferrocene to Transition-Metal Complexes Containing a Chelating 1,2-Dicarba-closo-dodecaborane-1,2-dichalcogenolate Ligand--in Vitro Cooperativity of a Ruthenium Compound on Cellular Uptake of an Anticancer Drug.

Computational and experimental examinations of new antitumor palladium(II) complex: CT-DNA-/BSA-binding, in-silico prediction, DFT perspective, docking, molecular dynamics simulation and ONIOM

Pincer-metal complexes possessing pyrrolidine: synthesis, structural characterization, and cytotoxicity

Crystal Design, Antitumor Activity and Molecular Docking of Novel Palladium(II) and Gold(III) Complexes with a Thiosemicarbazone Ligand

Synthesis of bimetallic palladacycles via C H bond activation: Crystal structure, DNA binding and in vitro cytotoxicity study